MSD withdraws SGLT2 inhibitors in a row
By Lee, Hye-Kyung | translator Kim, Jung-Ju
24.03.16 05:50:40
가나다라
0
Due to a decrease in market demand, MSD has decided to discontinue distribution after the final import this year
Last year, MSD voluntarily withdrew a metformin combination therapy, 'Segluromet'
MSD Korea is facing tough competition in the market for SGLT-2 inhibitors in South Korea.
MSD decided that they will discontinue the supply of Steglatro Tab 5 mg and 'Stegluzan Tab 5/100 mg (ertugliflozin plus sitagliptin)' after voluntarily withdrawing 'Steglatro Tab 15 mg (ertugliflozin)' and metformin combination therapy, 'Segluromet,' last year.

▲The list of approved and withdrawn SGLT-2 inhibitors by MSD in South Korea. Except for Stegluzan Tab 15/100 mg, all of MSD
According to the Ministry of Food and Drug Safety (MFDS) report on the 15th, supply discontinuation was reported for Steglatro Tab 5 mg and Stegluzan Tab 5/100 mg.
Imports of Steglatro Tab 5 mg will end on May 31st and Stegluzan Tab 5/100 mg will end on August 30th, after which these drugs will be discontinued.
<
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)